For the Inventor, By the Inventor

Enter assignee name

Morris Plains, NJ, United States of America

Immunomedics, Inc.

USPTO Granted Patents = 410

% Expired Patents = 35.4

CIPO Patents = 17

EPO Patents = 72

Trademarks = 9

Forward Citations = 10,780

Loading Chart...

Loading Chart...

73 inventors (with patents filed for the assignee):

David M Goldenberg (299 out of 393 patents)

Hans J Hansen (179 out of 191 patents)

Serengulam V Govindan (111 out of 112 patents)

4. Chien-Hsing Chang (75 out of 140 patents)

5. Zhengxing Qu (63 out of 65 patents)

6. William John McBride (60 out of 85 patents)

7. Gary L Griffiths (56 out of 64 patents)

8. Sung-Ju Moon (28 out of 28 patents)

9. Edmund A Rossi (27 out of 77 patents)

10. Shui-on Leung (24 out of 24 patents)

11. Christopher A D'Souza (19 out of 19 patents)

12. Milton D Goldenberg (17 out of 26 patents)

13. David V Gold (12 out of 12 patents)

14. Thomas M Cardillo (9 out of 9 patents)

15. Jeng-Dar Yang (9 out of 9 patents)

Core Competencies:

Immunoconjugates

Antibody-Drug Conjugates

SN-38

Triple-Negative Breast Cancer

Hematologic Malignancies

Trop-2

Checkpoint Inhibitors

Therapeutic Antibodies

Combination Therapy

Microtubule Inhibitors

PARP Inhibitors

HLA-DR Antibodies

410 patents: Sort by Forward Citations

1. 12364761 - Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity (2025-07-22),

2. 12310958 - Antibody-drug conjugates and uses thereof (2025-05-27),

3. 12251441 - Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity (2025-03-18),

4. 11541047 - Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity (2023-01-03),

5. 11439620 - Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors (2022-09-13),

6. 11253606 - Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer (2022-02-22),

7. 11192955 - Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors (2021-12-07),

8. 11180559 - Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies (2021-11-23),

9. RE48751 - Immunoconjugates with an intracellularly-cleavable linkage (2021-09-27),

10. 11116846 - Antibody-drug conjugates and uses thereof (2021-09-14),

11. 11077201 - Immunoconjugates with an intracellularly-cleavable linkage (2021-08-03),

12. 11066468 - Immunoconjugates with an intracellularly-cleavable linkage (2021-07-20),

13. 11052156 - Antibody-drug conjugates and uses thereof (2021-07-06),

14. 11052081 - Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) (2021-07-06),

15. 11020489 - Immunoconjugates with an intracellularly-cleavable linkage (2021-06-01),

Company Overview

Immunomedics, Inc., based in Morris Plains, NJ, specializes in the development of innovative antibody-drug conjugates (ADCs) aimed at treating various cancers, including triple-negative breast cancer and hematologic malignancies. The company focuses on harnessing the power of immunoconjugates, utilizing technologies such as SN-38 and targeting Trop-2 to enhance therapeutic efficacy. Their research also explores the integration of checkpoint inhibitors and therapeutic antibodies, positioning them at the forefront of cancer treatment advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

410 Patents

#2 in Morris Plains, NJ

#60 in New Jersey

#1,146 in US

#2,287 in the World

Morris Plains, NJ, United States of America

Immunomedics, Inc.

Forward Citations = 10,780

73 inventors:

David M Goldenberg (299 out of 393 patents)

Hans J Hansen (179 out of 191 patents)

Serengulam V Govindan (111 out of 112 patents)

4. Chien-Hsing Chang (75 out of 140 patents)

5. Zhengxing Qu (63 out of 65 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Immunomedics, Inc.. Retrieved from https://idiyas.com/company/immunomedics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…